Formulation design and development of Orodispersible tablets of Levetiracetam

Levetiracetam is a medication used to treat epilepsy. It is used for partial onset, myoclonic or tonic clonic Seizures. It works by decreasing abnormal excitement in the brain. The Current research work is aimed at developing a formulate and evaluate of an orodispersible tablet dosage form of Levetiracetam. The target of these new oral dissolving/disintegrating dosage forms have generally been pediatric, geriatric, bedridden and developmentally disabled patients and also patients with persistent nausea, who are in traveling, or who have little or no access to water are also good candidates for ODTs Direct Compression method was employed for blending of drug with polymers in the given ratio as a Nine formulations. The prepared powder blends were then compressed into tablets using the necessary Superdisintegrants (CP, SSG and CCS) and Excipients. The tablets were evaluated for Weight variation, thickness, hardness, friability, Drug Content and Disintegrating Time (Sec) were subjected to a 20 minutes in vitro drug release studies (USP dissolution rate test apparatus II, 50 rpm, 370C ±0.50C) using phosphate buffer, pH 6.8 as a dissolution medium (900ml). The amount of Levetiracetam released from the tablet formulations at different time intervals was estimated using a UV spectroscopy method. The formulations that showed a considerable retardation of the drug release are considered promising. Among the nine formulations, F5 formulation containing Drug to Sodium Starch Glycollate (SSG) and Cross Povidone (CP) is optimized based on its ability to till 10 minutes of in-vitro dissolution time, and its Cumulative % drug release of the 99.82±0.37% of dissolution study.